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Aim: To investigate the association between vasculopathy and survival during experimental cerebral malaria
(ECM), and to determine whether targeting the endothelin-1 (ET-1) pathway alone or in combination with
the anti-malaria drug artemether (a semi-synthetic derivative of artemisinin) will improve microvascular
hemorrhage and survival.
Main methods: C57BL/6 mice infected with Plasmodium berghei ANKA (PbA) were randomly assigned to four
groups: no treatment, artemether treated, ETA receptor antagonist (HJP-272) treated, or HJP-272 and
artemether treated. The uninfected control mice were treated with HJP-272 and artemether. We analyzed
survival, cerebral hemorrhage, weight change, blood glucose levels and parasitemia.
Key ﬁndings: Our studies demonstrated decreased brain hemorrhage in PbA-infected (ECM) mice treated
when HJP-272, a 1,3,6-trisubstituted-2-carboxy-quinol-4-one novel ETA receptor antagonist synthesized by
our group, is used in conjunction with artemether, an anti-malarial agent. In addition, despite adversely
affecting parasitemia and weight in non-artemether treated infected mice, HJP-272, seemed to confer some
survival beneﬁt when used as adjunctive therapy, though this did not reach signiﬁcance.
Signiﬁcance: Previous studies demonstrate that the endothelin pathway is associated with vasculopathy, neu-
ronal injury and inﬂammation in ECM. As demonstrated here, components of the ET-1 pathway may be im-
portant targets for adjunctive therapy in ECM, and may help in preventing hemorrhage and in improving
survival when used as adjunctive therapy during malaria infection. The data presented suggest that our
novel agent, HJP-272, may ameliorate alterations in the vasculature which can potentially lead to inﬂamma-
tion, neurological dysfunction, and subsequent death in mice with ECM.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Cerebral malaria (CM) in humans is the deadliest complication of
Plasmodium falciparum infection, leading to encephalopathy and high
rates of mortality in developing countries. Numerous studies indicate
that alteration of the cerebral vasculature are crucial in the pathogenesis
of CM. Magnetic resonance studies of murine CM in vivo demonstrated
vascular damage, including edema, a reduction in brain perfusion,
breakdown of the blood brain barrier (BBB) and hemorrhage due to
inﬂammatory factors (Penet et al., 2005). Previously, we demonstratedert Einstein College ofMedicine
704, Bronx, NY 10461, United
sruisseaux).
Y-NC-ND license.that experimental CM (ECM) was associated with cerebral vasculopathy
with an increase in endothelin level, which resulted in a reduction in ce-
rebral blood ﬂow and neuronal dysfunction (Kennan et al., 2005;
Machado et al., 2006). These abnormalities resulted in cognitive deﬁcits
in ECM during acute infection and after successful antimalarial therapy
(Desruisseaux et al., 2008; Dai et al., 2010).
Endothelin-1 (ET-1) in the brain is increasingly recognized as
a contributor in the pathogenesis of CM. It is a very potent vasocon-
strictor, which can be produced in vascular endothelial cells as well as
neurons and astrocytes (Kedzierski and Yanagisawa, 2001; Schinelli,
2002). ET-1 has several pharmacological effects on vasculature medi-
ated through the ET receptors (ETA or ETB) (Arai et al., 1990). The pre-
dominant biological effects produced by ET-1 are vasodilation through
activation of the ETB receptor and vasoconstriction and smoothmuscle
cell proliferation through the activation of the ETA receptor (Douglas
and Ohlstein, 1997). Elevated concentrations of ET-1 lead to increased
Fig. 1. HJP-272 structure andExperimentalDesign: (A) Chemical structureof selective ETA re-
ceptor antagonist (HJP-272) 1,3,6-trisubstituted-2-carboxy-quinol-4-one. (B) PbA-infected
mice were randomly assigned to four groups with different treatments. Uninfected control
mice were treated with HJP-272 (ETARB) 50 mg/kg via intraperitoneal (IP) injection and
artemether 50 mg/kg IP. n=7mice per group. ETARB=HJP‐272.
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mediating inﬂammation-induced vasoconstriction, resulting in re-
duction of cerebral blood ﬂow. Moreover, ET-1's participation in the
inﬂammatory process is believed to contribute to vascular dysfunction
and disruption of the integrity of the BBB (Teder and Noble, 2000;
Matsuo et al., 2001).
Current antimalarial drugs such as artemether have been used as
therapeutic treatments in the prevention of severe malaria in most
sub-Saharan African countries (Frosch et al., 2011). Although artemether
is a particularly useful antimalarial treatment, cognitive deﬁcits of
CM persist after successful cure of the infection as antimalarials only
eradicate the parasites, but do not provide neuroprotection (Sinclair
et al., 2009). Consequently, achieving a parasitological cure is insufﬁ-
cient in the amelioration and/or protection of the neurological dysfunc-
tion caused by malaria. Therefore, it is necessary to develop adjunctive
therapies directed at the prevention of neuronal dysfunction.
ET-1's facilitation in inﬂammation-induced vasoconstriction plays
a key role in the pathogenesis of CM, perhaps serving as an important
target for prevention of neuronal damage. To determine whether
targeting the ETA receptor has the potential to attenuate neurological
deﬁcits in ECM, a series of novel ETA receptor antagonists was designed
and synthesized. Comparativemolecular ﬁeld analysis was used to iden-
tify regions of the molecule that could accommodate various sub-
stituents and a structure activity relationship was performed. The most
potent analog in the series reduces ET-1 binding to the receptor by 50%
at nano-molar concentrations. Use of this novel ETA receptor blocker,
1,3,6-trisubstituted-2-carboxy-quinol-4-one (HJP-272), resulted in at-
tenuation of hemorrhage in the brain of mice infected with PbA, which
may provide the neural protection necessary in the treatment of CM.
Materials and methods
Ethics statement
This study was performed in strict accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health. The experiments were approved
by the Institutional Animal Care and Use Committee of the Albert
Einstein College of Medicine. All efforts were made to minimize
suffering.
Endothelin receptor antagonist
A novel ETA receptor antagonist, 1,3,6-trisubstituted-2-carboxy-
quinol-4-one (HJP-272; Fig. 1A), was synthesized by our group
using comparative molecular ﬁeld analysis (CoMFA) as previously
reported (Patet et al., 2010). It was used as one of the treatments to
examine the role of the ETA receptor in neuroprotection in combina-
tion with artemether, a semi-synthetic ether derivative of artemisinin
used in the treatment of malaria. Artemisinin derivatives have been
shown to be particularly effective in the treatment of cerebral malaria
[Klayman, 1985; Barnes et al., 2009].
Animal infection and study design
Six-week-old female C57BL/6 mice (Charles River Laboratories,
Wilmington, MA) were infected via intraperitoneal (IP) injection
with 105 Plasmodium berghei ANKA (PbA) parasitized RBCs. The
infected mice were randomly assigned to four groups: no treatment,
artemether treated (50 mg/kg; IP injection; Cabrales et al., 2010),
the novel ETA receptor antagonist (HJP-272) treated at a dose of
50 mg/kg via IP injection, or HJP-272 and artemether treated
(Fig. 1B; n=7 in each group). The HJP-272 dose chosen was previously
established to have the most reliable biological effect without evidence
of toxicity (Olgun et al., 2010). The uninfected controlmicewere treated
with HJP-272 and artemether (Fig. 1B; n=7 in each group). Tail bloodsmears of infected mice were stained with modiﬁed Giemsa stain
(Sigma-Aldrich, St Louis, MO) and examined daily under a light mi-
croscope from day 4 post-infection (PI) for parasitemia (deﬁned as
percentage of parasitized RBCs). Weight and blood glucose were mea-
sured at days 0, 2, 4 and every day from day 6 PI. Mice were examined
daily for locomotor activity and coat condition.
Treatment with either HJP-272, 50 mg/kg via intraperitoneal (IP)
injection, or vehicle was initiated at day 3 PI for all mice and continued
for 7 days. For treatment with artemether, infected mice were allowed
to manifest features of ECM, then treated with either artemether at a
dose of 50 mg/kg via IP injection for 5 days in order to eradicate para-
sites or were given no antimalarial therapy (injected with vehicle).
Artemether treatment was initiated when infected mice reached 3
pre-determined criteria as previously reported (Dai et al., 2010) brieﬂy,
weight loss, signiﬁcant change in glucose from baseline (hypo or hyper-
glycemia) and decreased activity. Artemether therapy was initiated at
day 7 PI in all uninfected control mice, the earliest day inwhich infected
mice received treatment with artemether. Mortality was recorded and
mice without artemether therapy were euthanized using carbon diox-
ide at day 8 or day 9 PI. Mice treated with artemether were euthanized
5 days after cessation of artemether. Brains were harvested and divid-
ed down the midline. For histology one half of the brain was ﬁxed in
10% normal buffered formalin (NBF) and stored at room temperature.
Histology
Brain tissue was ﬁxed, embedded in parafﬁn then sectioned into
4 μm sagittal slices at the midline. Brain sections were stained with
hematoxylin–eosin. Two separate sagittal sections were examined for
each animal (n=5 PbA+HJP-272; 4 PbA+HJP-272+Artemether; 3
PbA+Artemether; 9 PbA and 6 uninfected controls. For the purposes
of histological analysis, brain sections of 7 untreated PbA mice from
parallel replicate experiments using the same parameters as those uti-
lized in this experiment were used in order to increase the number of
mice analyzed (n=9 for PbA mice). Photographs were taken using a
Nikon Microphot-FXA microscope system and a Nikon digital sight
DS-5 M camera (Nikon Corporation, Japan). Examiners blinded to the
conditions of the specimens reviewed the stained sagittal sections
using a semi-quantitative method for hemorrhage analysis based on a
scale of 0–4 as previously reported (Dai et al., 2010) Brieﬂy 0=red
blood cells (RBCs) are conﬁnedwithin the blood vessels; 1=one vessel
with minimal extravasation of RBCs in one ﬁeld at 10× magniﬁcation;
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extensive extravasation; 4=greater than 1 vessel with extensive
extravasation.
Statistical analysis
Hemorrhage scores, percentage of weight change, percentage
of glucose change and parasitemia were statistically analyzed by
t-tests, one-way ANOVA with post-hoc Tukey's multiples comparison
analysis and 2-way ANOVA with post-hoc Bonferroni analysis using
GraphPad Prism v5.04 (GraphPad Software, La Jolla, California). Sur-
vival data was analyzed by the Kaplan–Meier and logrank test with
GraphPad Prism.Fig. 2. Parasitemia, weight loss, glucose change, survival and activity levels: (A) By 6 dpi, par
resulted in higher parasitemia than vehicle at 6 days post-infection (dpi) (F1,83=7.72; p
parasitemia on subsequent days. All mice treated with artemether had resolution of their
after infection with signiﬁcant decrease occurring after 6 dpi (F4,30=6.07; pb0.01), and a n
icantly greater weight loss than vehicle in non-artemether treated infected mice (F1,31=
increased to original levels after artemether treatment (15 dpi). (C) Infection with P. berghe
trols in all treatment groups with infection conferring higher glucose levels at terminal stage
did not independently affect glucose, it resulted in a signiﬁcant delay in the time taken to de
treated mice v. Day 7 in vehicle treated mice; F5,107=3.78; pb0.01). Likewise, in infected mi
surements, it contributed to attenuation of the hyperglycemia observed at day 7 (F7,123=2
dpi. (D) Kaplan–Meier survival curves in PbA-infected mice are signiﬁcantly different when
of infected mice. Likewise, treatment with HJP-272 alone did not result in improved surviv
survival when compared to PbA-infected mice with and without artemether that did not re
0.057 respectively). There was no difference in survival between infected mice with combin
decreases in weight compared to uninfected control groups regardless of treatment. Lik
PbA-infected mice had a signiﬁcantly lower activity levels than uninfected control mice at
the number of rears (F2,17=106.7; pb0.0001) in 1 minute (Fig. 2E). There were no effects o
plotted as mean±standard error (SEM). ETARB=HJP‐272. *pb0.05, **pb0.01.Results
Effects of HJP-272 on parasitemia, activity, weight and glucose
Infected mice receiving no anti-parasitic treatment experienced a
gradual increase in parasitemia, with greater than 7% infected red
blood cells (iRBCs) at 6 dpi and a peak at 9 dpi (PbA+HJP-272
20.5±5.1% v. PbA 18.2±1.8%, p=NS; Fig. 2A). Although parasitemia
in the infectedmice treatedwith artemetherwas greater than 7% iRBCs at
the beginning of artemether treatment (PbA+HJP-272+Artemether
12.8±1.3% v. PbA+Artemether 14.1±2.1%, p=NS; Fig. 2A), 3 days
after initiation of artemether treatment parasitemia returned to
0% (Fig. 2A). There was a signiﬁcant effect of HJP-272 therapy onasitemia was greater than 7% in all PbA-infected mice. Treatment with HJP-272 (ETARB)
b0.01). However, this effect was only transient as there were no further effects on
parasitemia by 9 dpi. (B) Infected animals demonstrated a gradual decrease in weight
adir occurring after 7 dpi (F4,26=10.07; pb0.0001). HJP-272 therapy resulted in signif-
17.02; pb0.001), with this effect being evident at 9 dpi. Weights of infected animals
i ANKA (PbA) signiﬁcantly affected serum glucose when compared to uninfected con-
s of disease (7 and 8 dpi in non-artemether treated mice). Though therapy with HJP-272
velop hyperglycemia in infected mice without artemether treatment (day 8 in HJP-272
ce treated with artemether, though HJP-272 did not independently affect glucose mea-
.12; pb0.05). All surviving infected mice recovered stabilization of blood glucose by 15
compared to controls. Treatment with artemether alone had no effect on the mortality
al. When used in combination with artemether, HJP-272 seemed to result in improved
ceive therapy; however, this did not quite reach statistical signiﬁcance (p=0.054 and
ed treatment and uninfected control mice. (E) Infection with PbA conferred signiﬁcant
ewise, infection with PbA resulted in wide ﬂuctuations in glucose starting at 7 dpi.
7 dpi as demonstrated by the number of grids crossed (F2,17=113.3; pb0.0001) and
f HJP-272 therapy on the activity levels of infected mice. Initial n=7 per group; Values
690 M. Dai et al. / Life Sciences 91 (2012) 687–692parasitemia levels in all infectedmice prior to institution of artemether
treatment, with HJP-272 resulting in higher parasitemia than vehicle
(F1,83=7.72; pb0.01). However, this effect was only transient and oc-
curred at 6 days post-infection (dpi) in non-artemether treated mice.
As previously stated, mice treated with artemether had resolution of
parasitemia regardless of HJP-272 administration.
PbA-infected mice had a signiﬁcantly lower activity levels than
uninfected control mice at 7 dpi as demonstrated by the number
of grids crossed (F2,17=113.3; pb0.0001) and the number of rears
(F2,17=106.7; pb0.0001) in 1 minute (Fig. 2E). There were no effects
of HJP-272 therapy on the activity levels of infected mice.
All infectedmice showedﬂuctuations inweight over time (illustrated
as the percent change fromoriginalweight) during active infection,with
signiﬁcant decreases of original body weight, compared to uninfected
control mice, starting at 6 dpi (F4,30=6.07; pb0.01; Fig. 2B) and a
nadir occurring after 7 dpi (F4,26=10.07; pb0.0001; Fig. 2B, E).
HJP-272 therapy resulted in signiﬁcantly greater weight loss than vehi-
cle in non-artemether treated infected mice (F1,31=17.02; pb0.001),
with this effect being evident at 9 dpi. All artemether-treated infected
mice recovered their baseline weight by 15 dpi.
Infection with P. berghei ANKA (PbA) signiﬁcantly affected serum
glucose when compared to uninfected controls in all treatment groups
(with and without artemether and with and without HJP-272) with in-
fection conferring higher glucose levels at terminal stages of disease
(Fig. 2C). Though therapy with HJP-272 did not independently affect
glucose, it resulted in a signiﬁcant delay in the time taken to develop
hyperglycemia in infected mice without artemether treatment (F5,107=
3.78; pb0.01). Likewise, in infectedmice treatedwith artemether, though
HJP-272 did not independently affect glucose measurements, it con-
tributed to attenuation of the hyperglycemia observed at day 7
(F7,123=2.12; pb0.05). All surviving infected mice recovered stabiliza-
tion of blood glucose by 15 dpi (Fig. 2C).
Effects of HJP-272 on survival
Mice receiving artemether treatment were sacriﬁced 5 days after the
cessation of artemether. Mice without artemether treatment were
sacriﬁced at 9 dpi. At 9 dpi, Kaplan–Meier survival curves were plotted
and differences in rates of survival in the various groups were observed:
PbA+HJP-272+Artemether 85.7%; PbA+Artemether 28.6%; PbA+
HJP-272 42.8%; and PbA 28.6%. Signiﬁcant effect of PbA-infection on
survival was demonstrated by the Logrank test with infected mice
having signiﬁcantly higher mortality than uninfected controls (Fig. 2D;
pb0.05). Treatment with artemether alone had no effect on the mor-
tality of infected mice. Likewise, treatment with HJP-272 alone did not
result in improved survival.When used in combinationwith artemether,
HJP-272 seemed to result in improved survival when compared to
PbA-infected mice with and without artemether that did not receive
therapy; however, this did not quite reach statistical signiﬁcance (p=
0.054 and 0.057 respectively). There was no difference in survival be-
tween infected mice with combined treatment and uninfected control
mice (Fig. 2D). Furthermore, there was no mortality observed in the
uninfected control group treated with HJP-272 and artemether, indicat-
ing that combined treatment with these two drugs had no potential
toxicity (Fig. 2D).
Effect of HJP-272 on brain hemorrhage
Hematoxylin and eosin (H&E) staining of sagittal brain sections
demonstrated signiﬁcant group effects on microvascular hemorrhage
(Fig. 3), with PbA infectionwith orwithout artemether therapy resulting
in higher hemorrhage scores in the olfactory bulb (F4,17=4.74; pb0.01),
the thalamus (F4,21=4.64; pb0.01), the hypothalamus (F4,23=4.29;
pb0.01) and the brainstem (F4,23=8.65; pb0.001) than in uninfected
controls. Interestingly, the degree of microvascular hemorrhage in-
duced by PbA infection continued to progress in the thalamus, thehypothalamus and in the brainstem despite treatmentwith artemether,
indicating that during acute disease, anti-malarial treatment alone was
not sufﬁcient to halt damage to cerebral microvessels despite effec-
tive clearance of parasites from the blood. Adjunctive therapy with
HJP-272, in combination with artemether, signiﬁcantly lessened
hemorrhage in the olfactory bulb, the thalamus and the brainstem
(Fig. 3).
Discussion
In the current study, we employed HJP-272, a novel ETA receptor
antagonist synthesized by our group to determine the role of ET-1
during ECM and to ascertain the antagonist's ability to ameliorate
brain microvascular damage and survival during severe disease. A
signiﬁcant attenuation of hemorrhage was observed in PbA-infected
mice treated with a combination of HJP-272 and artemether in the
regions of the brainstem, the thalamus and the olfactory bulb. In ad-
dition, therapy with HJP-272 helped ameliorate or helped delay, in
artemether-treated and non‐artemether-treated infected mice re-
spectively, wide ﬂuctuations in blood glucose induced by infection.
Furthermore, HJP-272 seemed to confer a synergistic survival beneﬁt
when combined with artemether which was independent of its effect
on hemorrhage and which was not due to any unintended intrinsic
antimalarial effect as PbA-infected mice treated with HJP-272 devel-
oped parasitemias that were either comparable or higher than the
untreated infected mice. Interestingly, treatment with HJP-272 in
fact resulted in an initial worsening in parasitemia which resolved
as disease progressed, suggesting that endothelin may play a protective
role in the control of parasitism during early infection. This phenomenon
has also been observed during treatment with other parasitic diseases
(Camargos et al., 2002).
We and others have previously demonstrated persistent working
and spatial memory deﬁcits with ECM which mimics the process
seen in survivors of pediatric CM (Dai et al., 2010; Reis et al., 2010).
Subcortical regions of the brain, including the thalamus, are intricately
involved in spatial learning and memory (Davoodi et al., 2009; Lopez
et al., 2009). The lesions in the thalamus observed in out ECM mice,
both prior to anti-malarial treatment and after artemether therapy,
may be involved in the memory deﬁcits previously recorded in our
mouse model. ET-induced vasculopathy may play an important role
in the decline in memory in ECM as adjunctive therapy with an ETA re-
ceptor antagonist ameliorated hemorrhage in that region of the brain.
These ﬁndings underscore the need for future studies correlating
improvement in microvascular hemorrhage to cognitive dysfunction
both during acute infection and after treatment with an anti-malarial
agent.
Endothelial inﬂammation and a hyper-active immune response,
including elevated levels of the pro-inﬂammatory cytokines TNF-α,
IFN-γ and IL-1, are hallmarks of severe malaria (Akanmori et al., 2000;
Wenisch et al., 1996). Both human and experimental studies indicate
that encephalitis resulting from CM is related to the production of
inﬂammatory mediators, leading to an activation of cerebral vascular
endothelium ( Akanmori et al., 2000; Hunt and Grau, 2003). We have
previously demonstrated that vasculopathy and cognitive dysfunction
in ECM highly correlate with inﬂammation throughout the brain
(Kennan et al., 2005; Desruisseaux et al., 2008). In this regard, it has
been reported that abnormal levels of ET-1 result from damaged or
ischemic endothelial and epithelial cells and have been linked to the
induction of this dysregulated inﬂammation (Lou et al., 2001; Sibson
et al., 2002). Overexpression of ET-1 has been demonstrated to activate
macrophages via stimulation of pro-inﬂammatory transcription factor
NF-κB, leading to production of pro-inﬂammatory cytokines, such as
TNF-α and IL-1 (Bohm and Pernow, 2007; Shao et al., 2011). Moreover,
ET-1 induces the release of monocyte chemoattractant protein-1
(MCP-1), which promotes an inﬂammatory response (Sutcliffe et al.,
2009). These immune responses likely contribute to vascular dysfunction
Fig. 3. Pathology of ECM with different treatments: While control mice treated with HJP-272 (ETARB) and artemether demonstrated no hemorrhage (A), PbA infected mice
displayed a signiﬁcant degree of hemorrhage (D — arrow; F) in several regions of the brain, particularly in the brainstem (F4,23=8.65; pb0.001), and the olfactory bulb (F4,17=4.74;
pb0.01). (B — arrows; F) HJP-272 treatment alone improved hemorrhage in the brainstem. (E; F) Even with artemether treatment, PbA infected mice still have signiﬁcant hemorrhage
which worsened despite treatment in the brainstem (E- arrow), the thalamus (F; F4,21=4.64; pb0.01), and the hypothalamus (F; F4,23=4.29; pb0.01). (C; F) Combined treatment with
HJP-272 and artemether improved hemorrhage in the brainstem (C- arrow), the thalamus and the olfactory bulb (F). n=9 PbA-infected mice with no treatment; 6 uninfected controls;
6 PbA-infected mice with both artemether and HJP-272; 5 PbA-infected mice with HJP-272 alone; 3 PbA-infected mice with artemether alone. ETARB=HJP‐272. *pb0.01.
691M. Dai et al. / Life Sciences 91 (2012) 687–692and potential downstream dysregulation with resulting neurologi-
cal sequelae. Therefore, regulation of ET-1's action via ETA receptor
antagonists may increase the survival in ECM by attenuating the
associated inﬂammation in addition to its protective effects on the
vasculature.
The ETA receptor is found on various neurons and mediates both
vasoconstriction and signal transduction in the brain (Yamada and
Kurokawa, 1998; Douglas and Ohlstein, 1997). Intraventricular admin-
istration of ET-1 in conscious rats resulted in behavioral, physiological
and hypermetabolic effects. Most of these effects occurred at the doses
that cause no changes in cerebral blood ﬂow (Douglas and Ohlstein,
1997). Injection of ET-1 into dorsolateral periaqueductal gray matter
of mice reduced pain response in a dose-dependent manner (D'Amico
et al., 1996). These data suggest that ETA plays a role in neurotransmis-
sion that is necessary in CNS function. ET-1was also found to exacerbate
apoptosis and neuronal cell death during ischemic conditions through
activation of its receptor (Leung et al., 2004; Taylor et al., 2004).
In an ischemic brain, ET-1 induces a decrease in glutamate uptake by
reducing glutamate transporters in astrocytes and enhances glutamate
excitotoxicity, resulting in intensifying neuronal damage (Ishibashi et
al., 2001; Montgomery et al., 2006). Recent evidence implicated that
ET-1 modulates glutamate release onto magnocellular neurons in the
supraoptic nucleus (Zampronio et al., 2010). Controlling ET-1's action
therefore may also reduce ischemic brain damage and restore proper
regulation of glutamate.
Finally, ET-1 may regulate glucose metabolism in ECM. Infected
mice treated with both the ETA receptor antagonist and artemetherhad more stable blood levels of glucose than infected mice treated with
artemether alone. Furthermore, in infected mice with no anti-malarial
treatment, administration of the ETA receptor antagonist resulted in a
delay in the volatile ﬂuctuations in blood glucose. Chronic treatment
with ET-1 has been demonstrated to reduce insulin signaling by induc-
ing degradation of the insulin receptor substrate 1 (IRS-1) and inhibi-
tion of insulin-stimulated tyrosine phosphorylation of IRS-1 (Ishibashi
et al., 2001; Usui et al., 2005). It is possible that the ETA receptor antag-
onist may improve both neurological function and survival in ECM by
restoring proper insulin signaling and hence proper regulation of glu-
cose metabolism.
It is important to note that though treatment with the anti-malarial
agent, artemether alone or with HJP-272 alone did not have any effect
on survival, we observed a synergistic improvement in survival in
mice treated with HJP-272 combined with artemether. Though this
did not quite reach signiﬁcance due to the initial number of mice in
our experiment, it was nonetheless an important observation which
suggests that mechanisms beyond either drug's effects on hemorrhage
are important in the management of ECM, and which warrants further
investigation. In this regard, treatment with HJP-272 ameliorated
hemorrhagic damage in the brainstem. Irreversible brainstem glial
cell injury and dysfunction have been described in cases of severe
human CM (Medana et al., 2001). ET-1 induced increase in hemorrhagic
damage in the brainstem observed during infection in our model not
only point toward damage to the central respiratory center as a possible
explanation for the increased mortality associated with ECM despite
treatmentwith artemether, but itmay also be implicated in downstream
692 M. Dai et al. / Life Sciences 91 (2012) 687–692neuronal and glial cell damage with ECM. Adjunctive administration
of HJP-272 resulted in signiﬁcant amelioration of this damage to the re-
spiratory center and may be important in future survival studies using
this model.
There was a progression of vascular damage in the brain after suc-
cessful treatment of acute malarial disease with artemether, particu-
larly in the brainstem, the thalamus and the hypothalamus. This is
different from our previous observations of resolved hemorrhage
with anti-parasitic treatment (Dai et al., 2010); however the mice in our
previous studies were examined long after completion of a prolonged
chloroquine course, i.e. 21 days after completion of a 10-day course of
chloroquine long after the resolution of acute disease, and not during
the acute process as with this study where mouse brains were examined
5 days after a 5-day course of artemether.
Cerebral malaria is a potentially fatal disease characterized by irre-
versible neurological insults. In this study, we have identiﬁed a possible
therapeutic candidate that regulates the inﬂammatory ET-1 pathway,
hence decreasing the hemorrhage in the brain microvasculature in
mice infected with PbA. Whether the improvement in vascular damage
results in proper restoration of CNS function and whether the drug re-
verses the long-term cognitive deﬁcits associated with severe disease
still needs to be determined. However, based on these initial tests, this
antagonist presents a promising adjunctive agent for the management
of cerebral malaria.
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